Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q4 earnings. Here is a breakdown of the information Annexon Biosciences, Inc. presented to ...

GBS is a rare, neuromuscular emergency that affects at least 150,000 people worldwide each year, with no FDA-approved therapy. The life-altering consequences of GBS were recently detailed in a new ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory ...